Natasha holds first-class honors in Biological Sciences from the University of Leeds. She completed an industrial placement with Johnson & Johnson during her degree, working in medical device regulatory affairs. After graduating from university, she worked for regulatory consultancy firm JensonR+ across medicines, medical devices, food supplements, and cosmetics. In 2022, she moved to London to work for the UK consumer healthcare association. She joined Medtech Insight in November 2023 and reports on the latest commercial and policy developments in diagnostics and AI digital technologies, covering therapeutic areas such as cancer and cardiology.
Latest from Natasha Barrow
Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.
Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.
NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.
"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.